Catridecacog

Drug Profile

Catridecacog

Alternative Names: NN-1810; NN-1841; NN8717; NovoThirteen; Recombinant factor XIII - Novo Nordisk; Recombinant human factor XIII - Novo Nordisk; rFXIII - Novo Nordisk; rhFactor-XIII - Novo Nordisk; rhFXIII - Novo Nordisk; Tretten

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator ZymoGenetics
  • Developer Novo Nordisk
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Factor XIII deficiency
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Factor XIII deficiency
  • No development reported Postoperative haemorrhage; Ulcerative colitis

Most Recent Events

  • 03 Dec 2016 Efficacy and adverse events data from the mentor™2 phase III trial in Factor XIII deficiency presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
  • 26 Oct 2015 Novo Nordisk completes a phase III extension trial in Factor XIII deficiency in the USA, Canada, European Union, Israel, Japan and Switzerland (NCT00978380)
  • 09 Mar 2015 Catridecacog is still in phase III trials for Factor XIII deficiency (In infants, In children) in Israel, United Kingdom and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top